Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration to commence a Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis .
http://www.benzinga.com/news/13/04/3503567/neuralstem-wins-fda-approval-to-begin-phase-ii-stem-cell-trial-in-amytrophic-late
http://www.benzinga.com/news/13/04/3503567/neuralstem-wins-fda-approval-to-begin-phase-ii-stem-cell-trial-in-amytrophic-late
No comments:
Post a Comment